CO2020005223A2 - Terapias de combinación y usos de las mismas - Google Patents
Terapias de combinación y usos de las mismasInfo
- Publication number
- CO2020005223A2 CO2020005223A2 CONC2020/0005223A CO2020005223A CO2020005223A2 CO 2020005223 A2 CO2020005223 A2 CO 2020005223A2 CO 2020005223 A CO2020005223 A CO 2020005223A CO 2020005223 A2 CO2020005223 A2 CO 2020005223A2
- Authority
- CO
- Colombia
- Prior art keywords
- combination therapies
- immune response
- preventing tumor
- inducing
- enhancing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente descripción se refiere a terapias de combinación que contienen uno o más inhibidores de PARP y uno o más inhibidores de angiogénesis. También se describen en el presente documento usos terapéuticos de tales terapias de combinación para tratar diversos trastornos y afecciones. Las terapias de combinación y sus usos pueden ser útiles para prevenir el crecimiento de células tumorales, prevenir metástasis tumorales, inducir una respuesta inmunológica o mejorar una respuesta inmunológica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762569239P | 2017-10-06 | 2017-10-06 | |
PCT/US2018/054606 WO2019071123A1 (en) | 2017-10-06 | 2018-10-05 | POLYRHEERAPIES AND USES THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020005223A2 true CO2020005223A2 (es) | 2020-05-15 |
Family
ID=64051695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0005223A CO2020005223A2 (es) | 2017-10-06 | 2020-04-27 | Terapias de combinación y usos de las mismas |
Country Status (17)
Country | Link |
---|---|
US (1) | US11801240B2 (es) |
EP (1) | EP3691685A1 (es) |
JP (1) | JP2020536869A (es) |
KR (1) | KR20200067164A (es) |
CN (1) | CN111182923A (es) |
AU (2) | AU2018346688A1 (es) |
BR (1) | BR112020006845A2 (es) |
CA (1) | CA3076859A1 (es) |
CL (2) | CL2020000907A1 (es) |
CO (1) | CO2020005223A2 (es) |
EA (1) | EA202090655A1 (es) |
IL (1) | IL273510A (es) |
MA (1) | MA50618A (es) |
MX (1) | MX2020003799A (es) |
PH (1) | PH12020550400A1 (es) |
SG (1) | SG11202002499TA (es) |
WO (1) | WO2019071123A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020512350A (ja) | 2017-03-27 | 2020-04-23 | テサロ, インコーポレイテッド | ニラパリブ組成物 |
CA3060715A1 (en) | 2017-04-24 | 2018-11-01 | Tesaro, Inc. | Methods of manufacturing of niraparib |
CA3063715A1 (en) | 2017-05-18 | 2018-11-22 | Tesaro, Inc. | Combination therapies for treating cancer |
BR112020006039A2 (pt) | 2017-09-26 | 2020-10-06 | Tesaro, Inc. | formulações de niraparibe |
KR20200086664A (ko) | 2017-09-30 | 2020-07-17 | 테사로, 인코포레이티드 | 암을 치료하기 위한 조합 요법 |
WO2019071123A1 (en) | 2017-10-06 | 2019-04-11 | Tesaro, Inc. | POLYRHEERAPIES AND USES THEREOF |
EP3721906A4 (en) * | 2017-12-06 | 2021-08-04 | Jiangsu Hengrui Medicine Co., Ltd. | USE OF PARP INHIBITOR TO TREAT CHEMOTHERAPY RESISTANT OVAR CANCER OR BREAST CANCER |
US20220319704A1 (en) | 2019-05-06 | 2022-10-06 | Tesaro, Inc. | Methods for characterizing and treating a cancer type using cancer images |
US20230123585A1 (en) * | 2020-03-03 | 2023-04-20 | The University Of Chicago | Compositions and methods for treating or preventing cancer using deubiquitinase inhibitors |
CN112007042B (zh) * | 2020-09-10 | 2023-02-21 | 中国医学科学院医学生物学研究所 | 阿糖胞苷与原癌蛋白c-FOS抑制剂在制备治疗白血病的产品中的应用 |
CN112316149A (zh) * | 2020-11-11 | 2021-02-05 | 王海涛 | 一种治疗tp53突变的晚期难治性实体瘤的药物及应用 |
KR20220085742A (ko) * | 2020-12-15 | 2022-06-22 | 칸트사이언스 주식회사 | 암 환자에서 혈관 신생 억제 및 항암제 치료 효과 증대용 조성물 |
CN114748479B (zh) * | 2021-01-08 | 2023-10-20 | 轩竹生物科技股份有限公司 | 一种预防和/或治疗癌症的药物组合物 |
CN115177621B (zh) * | 2021-04-02 | 2023-09-01 | 上海市第一人民医院 | Av-951在制备用于抑制或治疗甲状腺相关眼病的药物中的应用 |
CN113101288A (zh) * | 2021-05-08 | 2021-07-13 | 中国人民解放军空军军医大学 | 一种协同增效治疗脊索瘤的组合药物及其用途 |
CN114712515A (zh) * | 2022-03-30 | 2022-07-08 | 上海交通大学医学院附属瑞金医院 | 一种dll4抑制剂联合parp抑制剂在制备治疗卵巢癌药物中的应用 |
CN115177594B (zh) * | 2022-07-04 | 2023-08-15 | 武汉大学中南医院 | 一种阿昔替尼药物制剂及其制备方法 |
CN115154589B (zh) * | 2022-08-26 | 2024-04-09 | 山东大学 | 白藜芦醇联合成纤维细胞生长因子1在缓解蒽环类药物诱导的心脏及肝脏毒性中的应用 |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1333363C (en) | 1988-01-19 | 1994-12-06 | Judah Folkman | Angiogenesis inhibitor comprising fumagillin |
ATE106726T1 (de) | 1988-09-01 | 1994-06-15 | Takeda Chemical Industries Ltd | Angiogenese hemmendes mittel. |
PT2206517T (pt) | 2002-07-03 | 2023-11-07 | Tasuku Honjo | Composições de imunopotenciação contendo anticorpos anti-pd-l1 |
US9707302B2 (en) | 2013-07-23 | 2017-07-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
CA2647545C (en) | 2006-04-03 | 2016-02-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
GEP20115337B (en) | 2007-01-10 | 2011-11-25 | St Di Ricerche Di Biologia Molecolare P Angeletti Spa | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
RS53072B (en) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | HUMAN RECEPTOR ANTIBODIES PROGRAMMED DEATH PD-1 |
MX2010005221A (es) | 2007-11-12 | 2010-09-28 | Bipar Sciences Inc | Tratamiento de cancer de utero y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes antitumorales. |
CN103169973A (zh) | 2007-11-12 | 2013-06-26 | 彼帕科学公司 | 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌 |
EP2237684A2 (en) | 2008-01-08 | 2010-10-13 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
CN101932572A (zh) | 2008-01-08 | 2010-12-29 | 默沙东有限公司 | 2-{4-[(3s)-哌啶-3-基]苯基}-2h-吲唑-7-羧酰胺的药学可接受的盐 |
HUE034832T2 (hu) | 2008-12-09 | 2021-12-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására |
WO2010091140A1 (en) | 2009-02-04 | 2010-08-12 | Bipar Sciences, Inc. | Treatment of lung cancer with a parp inhibitor in combination with a growth factor inhibitor |
ES2646863T3 (es) | 2009-11-24 | 2017-12-18 | Medimmune Limited | Agentes de unión específica contra B7-H1 |
WO2011153383A1 (en) | 2010-06-04 | 2011-12-08 | Bipar Science, Inc. | Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound |
DK3012329T3 (da) | 2010-06-18 | 2017-11-20 | Myriad Genetics Inc | Fremgangsmåder og materialer til at vurdere tab af heterozygositet |
EP3109325B1 (en) | 2010-08-24 | 2018-12-26 | Dana-Farber Cancer Institute, Inc. | Methods for predicting anti-cancer response |
CA2742342A1 (en) | 2011-02-12 | 2012-08-12 | Baylor Research Institute | Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs |
JP6138813B2 (ja) | 2011-11-28 | 2017-05-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 抗pd−l1抗体及びその使用 |
CA2867434C (en) | 2012-06-07 | 2021-10-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
US9580407B2 (en) | 2012-12-07 | 2017-02-28 | Merck Sharp & Dohme Corp. | Regioselective N-2 arylation of indazoles |
ES2672328T3 (es) | 2012-12-07 | 2018-06-13 | Merck Sharp & Dohme Corp. | Proceso de transaminación biocatalítica |
US9850542B2 (en) | 2013-03-04 | 2017-12-26 | Board Of Regents, The University Of Texas System | Gene signature to predict homologous recombination (HR) deficient cancer |
AR095363A1 (es) | 2013-03-15 | 2015-10-14 | Genentech Inc | Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1 |
CN105339389B (zh) | 2013-05-02 | 2021-04-27 | 安奈普泰斯生物有限公司 | 针对程序性死亡-1(pd-1)的抗体 |
US11149316B2 (en) | 2013-12-09 | 2021-10-19 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors |
WO2015108986A1 (en) | 2014-01-16 | 2015-07-23 | Clovis Oncology, Inc. | Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity |
US20170175197A1 (en) | 2014-01-29 | 2017-06-22 | Caris Mpi, Inc. | Molecular profiling of immune modulators |
EP3148336B1 (en) | 2014-05-28 | 2019-10-02 | Eisai R&D Management Co., Ltd. | Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
US20150344968A1 (en) | 2014-05-30 | 2015-12-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods for determining parp inhibitor and platinum resistance in cancer therapy |
WO2016094391A1 (en) | 2014-12-08 | 2016-06-16 | Myriad Genetics, Inc. | Methods and materials for predicting response to niraparib |
MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
MA41867A (fr) | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) |
JP2018514550A (ja) | 2015-04-28 | 2018-06-07 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 抗pd−1抗体および抗ctla−4抗体を使用するpd−l1陰性黒色腫の処置 |
EP3303397A1 (en) | 2015-06-08 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
PL3313443T3 (pl) | 2015-06-25 | 2023-11-06 | Immunomedics, Inc. | Łączenie przeciwciał anty-hla-dr lub anty-trop-2 z inhibitorami mikrotubuli, inhibitorami parp, 5 inhibitorami kinazy brutona lub inhibitorami 3-kinazy fosfoinozytydu istotnie poprawia wynik terapeutyczny nowotworu |
JP7042739B2 (ja) | 2015-08-20 | 2022-03-28 | イプセン バイオファーム リミティド | 癌処置のためのリポソーム型イリノテカン及びparp阻害薬を使用する併用療法 |
CA3003422A1 (en) | 2015-10-26 | 2017-05-04 | Medivation Technologies Llc | Treatment of small cell lung cancer with a parp inhibitor |
ES2906813T3 (es) * | 2016-02-15 | 2022-04-20 | Astrazeneca Ab | Métodos que comprenden una dosificación intermitente fija de cediranib |
NZ749413A (en) | 2016-06-29 | 2023-05-26 | Tesaro Inc | Methods of treating ovarian cancer |
EP3519051B1 (en) | 2016-09-27 | 2021-09-22 | Beigene, Ltd. | Treatment of cancers using combination comprising parp inhibitors |
SG11201903867YA (en) | 2016-11-01 | 2019-05-30 | Anaptysbio Inc | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
MX2019005117A (es) | 2016-11-01 | 2019-10-21 | Anaptysbio Inc | Anticuerpos dirigidos contra la muerte programada 1 (pd-1). |
KR102606252B1 (ko) | 2017-01-09 | 2023-11-23 | 테사로, 인코포레이티드 | 항-pd-1 항체로 암을 치료하는 방법 |
EP3565594A1 (en) | 2017-01-09 | 2019-11-13 | Tesaro Inc. | Methods of treating cancer with anti-tim-3 antibodies |
WO2018183349A1 (en) | 2017-03-27 | 2018-10-04 | Tesaro, Inc. | Niraparib formulations |
JP2020512350A (ja) | 2017-03-27 | 2020-04-23 | テサロ, インコーポレイテッド | ニラパリブ組成物 |
CA3060715A1 (en) | 2017-04-24 | 2018-11-01 | Tesaro, Inc. | Methods of manufacturing of niraparib |
MX2019012793A (es) | 2017-04-27 | 2020-02-13 | Tesaro Inc | Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos. |
US20200289493A1 (en) | 2017-05-09 | 2020-09-17 | Tesaro, Inc. | Combination therapies for treating cancer |
CA3063715A1 (en) | 2017-05-18 | 2018-11-22 | Tesaro, Inc. | Combination therapies for treating cancer |
US20200129482A1 (en) | 2017-06-26 | 2020-04-30 | Abbvie Inc. | Treatment of non-small cell lung cancer |
BR112020006039A2 (pt) | 2017-09-26 | 2020-10-06 | Tesaro, Inc. | formulações de niraparibe |
KR20200086664A (ko) | 2017-09-30 | 2020-07-17 | 테사로, 인코포레이티드 | 암을 치료하기 위한 조합 요법 |
WO2019071123A1 (en) | 2017-10-06 | 2019-04-11 | Tesaro, Inc. | POLYRHEERAPIES AND USES THEREOF |
KR20200105862A (ko) | 2017-12-27 | 2020-09-09 | 테사로, 인코포레이티드 | 암을 치료하는 방법 |
KR20200118117A (ko) | 2018-02-05 | 2020-10-14 | 테사로, 인코포레이티드 | 소아용 니라파립 제제 및 소아용 치료 방법 |
EA201992594A1 (ru) | 2018-03-26 | 2020-03-20 | Тесаро, Инк. | Комбинированные терапии для лечения рака |
US11970530B2 (en) | 2020-08-13 | 2024-04-30 | Astrazeneca Ab | Methods of treating homologous recombination deficient cancer |
-
2018
- 2018-10-05 WO PCT/US2018/054606 patent/WO2019071123A1/en unknown
- 2018-10-05 MX MX2020003799A patent/MX2020003799A/es unknown
- 2018-10-05 CA CA3076859A patent/CA3076859A1/en active Pending
- 2018-10-05 AU AU2018346688A patent/AU2018346688A1/en not_active Abandoned
- 2018-10-05 EP EP18796190.9A patent/EP3691685A1/en not_active Withdrawn
- 2018-10-05 SG SG11202002499TA patent/SG11202002499TA/en unknown
- 2018-10-05 CN CN201880065336.2A patent/CN111182923A/zh active Pending
- 2018-10-05 BR BR112020006845-4A patent/BR112020006845A2/pt not_active Application Discontinuation
- 2018-10-05 EA EA202090655A patent/EA202090655A1/ru unknown
- 2018-10-05 US US16/754,083 patent/US11801240B2/en active Active
- 2018-10-05 JP JP2020519286A patent/JP2020536869A/ja active Pending
- 2018-10-05 MA MA050618A patent/MA50618A/fr unknown
- 2018-10-05 KR KR1020207012376A patent/KR20200067164A/ko not_active Application Discontinuation
-
2020
- 2020-03-23 IL IL273510A patent/IL273510A/en unknown
- 2020-04-03 PH PH12020550400A patent/PH12020550400A1/en unknown
- 2020-04-03 CL CL2020000907A patent/CL2020000907A1/es unknown
- 2020-04-27 CO CONC2020/0005223A patent/CO2020005223A2/es unknown
- 2020-11-13 CL CL2020002958A patent/CL2020002958A1/es unknown
-
2022
- 2022-03-21 AU AU2022201944A patent/AU2022201944A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EA202090655A1 (ru) | 2020-12-07 |
US20200306236A1 (en) | 2020-10-01 |
PH12020550400A1 (en) | 2021-03-08 |
JP2020536869A (ja) | 2020-12-17 |
AU2022201944A1 (en) | 2022-04-14 |
SG11202002499TA (en) | 2020-04-29 |
MA50618A (fr) | 2020-08-12 |
US11801240B2 (en) | 2023-10-31 |
CL2020002958A1 (es) | 2021-03-05 |
IL273510A (en) | 2020-05-31 |
CL2020000907A1 (es) | 2020-08-14 |
CA3076859A1 (en) | 2019-04-11 |
MX2020003799A (es) | 2020-11-06 |
BR112020006845A2 (pt) | 2020-10-06 |
WO2019071123A1 (en) | 2019-04-11 |
AU2018346688A1 (en) | 2020-04-23 |
KR20200067164A (ko) | 2020-06-11 |
CN111182923A (zh) | 2020-05-19 |
EP3691685A1 (en) | 2020-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020005223A2 (es) | Terapias de combinación y usos de las mismas | |
CL2017001464A1 (es) | Modulación inmunológica | |
DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
EA201790737A1 (ru) | Комбинированная терапия | |
CL2018003142A1 (es) | Moduladores de la vía de estrés integrada | |
AR113881A1 (es) | Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia | |
MX2021006581A (es) | Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia. | |
CR20180336A (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
MX2020006115A (es) | Inhibidores de la vía de respuesta al estrés integrada. | |
CL2017001514A1 (es) | Inhibidores de erk | |
GT201600233A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
BR112017003111A2 (pt) | composições e métodos para o tratamento de distúrbios neurológicos | |
CL2020003202A1 (es) | Piridinil y pirazinil-(aza)indolsulfonamidas | |
MA40437A (fr) | Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux | |
UY35464A (es) | Inhibidores covalentes de kras g12c. | |
CO2018005315A2 (es) | Moduladores de la interacción de sestrina-gator2 y sus usos | |
CL2015002807A1 (es) | Terapia de combinación | |
GT201400222A (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina | |
UY37349A (es) | Composiciones y métodos para inhibir masp-3 para el tratamiento de varias enfermedades y trastornos | |
MX364438B (es) | Inhibidores covalentes de kras g12c. | |
ECSP17013903A (es) | Protein kinase c inhibitors and methods of their use | |
EA202090632A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
NI201400111A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
CL2021001432A1 (es) | Terapia de combinación de radioinmunoconjugados con inhibidores de daños y reparaciones del adn |